abcam

ab24093

Anti-HL60 antibody [IPO-M6]

Key facts

Isotype	IgG1
Host species	Mouse
Storage buffer	pH: 7.3 Preservative: 0.05% Sodium azide Constituents: PBS
Form	Liquid
Clonality	Monoclonal
Immunogen	Cell preparation containing HL60 protein. The exact immunogen used to generate this antibody is proprietary information.
Clone number	IPO-M6
Purification technique	Affinity purification Protein G
Specificity	Reacts with human leukemia cell line HL60 and immuno-precipitates with two proteins with MW of 48 and 52 kDa. ab24093 does not stain B cell lines Daudy, PHS, Namalwa, RPMI-1788 and T-cell lines CCRF-HSB2, Jurkat and Molt-4.
Concentration	0.1 mg/mL The concentration of this product may be batch-dependent Batch concentration finder →

Reactivity data

IHC-Fr

Expected

Species	Human
Dilution info	Use at an assay dependent concentration.
Notes	-

Flow Cyt

Expected

Species	Human
Dilution info	Use at an assay dependent concentration.
Notes	-

IP

Expected

Species	Human
Dilution info	Use at an assay dependent concentration.
Notes	-

Target data

See full target information HL-60

Storage

Shipped at conditions	Blue Ice
Appropriate short-term storage conditions	+4°C
Appropriate long-term storage conditions	-20°C
Aliquoting information	Upon delivery aliquot
Storage information	Avoid freeze / thaw cycle

Notes

This antibody can be applied for staining of monocytes and up to 10 % of lymphocytes from peripheral blood of healthy donors. Blast cells of patients with AMMonL (M5 following FAB classification), AMMonL (M4) and hairy cells leukemia were ab24093 positive. The antigen, defined with this mAb, is particularly expressed on blood cells from

patients with infectious mononucleosis and CLL. Histiocytes and macrophages were also positive. Malignant cells from patients with AML (M1 and M2), T-ALL, B-ALL were ab24093 negative.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary	The HL60 cell line named for its original derivation from human promyelocytic leukemia serves as a model for studying various aspects of blood cell biology and cancer research. HL60 cells are suspension cells and feature the unique ability to differentiate into several cell types such as granulocytes and macrophage-like cells depending on the stimuli. The cells express markers for early hematopoietic progenitors as well as proteins relevant to immune response. Mass-specific information for the HL60 line is not applicable as it refers to a cell line rather than a solitary protein or molecule.
Biological function summary	HL60 cells provide insights into modulations within the hematopoietic lineage. Scientists frequently use it to study the process of myeloid differentiation offering a stable platform for experiments involving gene expression and genetic modifications. The cell line is not part of a specific protein complex but plays an essential role when studying signal transduction pathways affecting myeloid cell differentiation. Researchers widely apply these cells to analyze transcription factors and cytokine interactions.
Pathways	The HL60 cell line facilitates exploration of the mitogen-activated protein kinase (MAPK) pathway and the role it plays in cell proliferation and differentiation. This pathway interacts with key proteins such as extracellular signal-regulated kinases (ERK) and c-Jun N-terminal kinases (JNK) influencing cellular outcomes by receiving and interpreting a multitude of metabolic and external signals. HL60 serves as a powerful tool for dissecting molecular regulation and signal integration within these pathways.
Associated diseases and disorders	The HL60 cell line contributes significantly to the understanding of acute promyelocytic leukemia given its original derivation from this cancer type. Researchers employ these cells to test therapeutic interventions and understand drug resistance mechanisms related to leukemia. Moreover leading-edge studies utilize HL60 cells to explore the effects of new drugs targeting the modifications of the proteins involved in the disease such as PML-RARα the oncogenic driver in promyelocytic leukemia.

Product promise

Tested

We have tested this species and application combination and it works. It is covered by our product promise.

Expected

We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.

Predicted

This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.

Not recommended

We do not recommend this combination. It is not covered by our product promise.

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.